FDA Grants Fast Track to Faeth’s Metabolic Cancer Combo for Advanced Endometrial Cancer

The PI3K/AKT/mTOR pathway is altered in up to half of solid tumours and has resisted drugging. Faeth is blocking two points along it at once, in patients who have run out of options.

By RxWyre Editorial Desk · Aug 28, 2026 · 4 min read